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Chapter 1.  Introduction 
 
Use of the amorphous phase to improve the oral bioavailability of poorly soluble 
drugs is well known.    The amorphous phase is the higher energy form and as such offers 
the promise of greater solubility and faster dissolution rate which have the potential to 
increase bioavailability.
1,2
  However, amorphous materials are rarely used during drug 
development due to physical and chemical stability issues and processing difficulties.
3
  
The amorphous form tends to be more chemically unstable than their crystalline 
counterparts
4
  although from a development standpoint the physical instability raises the 
most challenges.  Physical instability leads to the transformation of the amorphous state 
to the thermodynamically favored crystalline state.  A typical approach to improve the 
physical stability of amorphous pharmaceuticals is to combine them with inactive 
ingredients such as polymers to form amorphous solid dispersions.   There are a number 
of reports describing the use of organic polymers to make amorphous solid dispersions.  
The solubility and dissolution advantage that can be obtained with these systems is seen 
both in vitro and in vivo.
7-12
 The organic polymers typically used are poly(vinyl 
pyrrolidone), polyethylene glycol, poly(methyl methacrylate) and cellulosic polymers.  
The exact mechanism of stabilization of the amorphous API by the organic polymer has 
not been fully determined.  It has been attributed to a number of reasons.  One is that 
intermolecular interactions between the polymer and the API are stabilized by hydrogen 
bonding.  Another is that the production of single phase mixtures of the polymer and the 
API leads to increased glass transition temperature and polymers providing a diffusional 
v 
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barrier to crystallization of the API.  Although a number of mechanisms for stabilization 
of the amorphous API by the organic polymers have been described, they all depend to 
some extent upon the physical interaction between the polymer and the drug. 
While there have been several studies done using organic excipients, the 
application of inorganic materials to improve the physical stability of amorphous API has 
not been explored in great detail.  Bogner et al. have reported the amorphization of three 
acidic drugs (Ketoprofen, Naproxen, and Indomethacin) and the basic drug progesterone 
when co-ground in a ball mill with Neusilin US2, a synthetic magnesium 
aluminometasilicate.  The amorphous state of the milled complex of all four drugs was 
found to be physically stable for up to 4 weeks when stored at 40
o
C/75%RH conditions.  
The physical stability of the amorphous phase of the acidic drug-Neusilin complexes 
were attributed to two different possible interactions.  The first mechanism proposed was 
an acid-base reaction between the carboxyl group of the acidic drug with the surface 
hydroxyl groups in Neusilin.  The second proposed mechanism is an ion-dipole 
interaction between the metal ions in Neusilin and the drug.  The stability of the 
amorphous progesterone-Neusilin complex was attributed to hydrogen bonding between 
the carbonyl group of progesterone and the silanol group of Neusilin. Bogner et al. have 
also reported the dependence of amorphization kinetics of Indomethacin on the weight 
ratio of Indomethacin to Neusilin used during co-grinding.  Watanabe et al.  have 
reported the formation of amorphous Indomethacin when co-ground with silica in a 
vibration mill.  Using 
13
C and 
29
Si solid state NMR they have concluded that the milling 
causes mechanochemical reactions between Indomethacin and the silanol groups on the 
surface of silica and the damaged siloxane bonds in the bulk of silica.   Kinoshita et al. 
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have reported the improvement in oral bioavailability of a development drug TAS 301 
when hot melt extruded with porous calcium silicate.  The amorphous phase produced 
after extrusion was found to be physically stable for a period of two years at ambient 
conditions.  The authors attributed the amorphous stability to the melt adsorption of the 
drug onto the porous silicate with the possibility of hydrogen bonding between the drug 
and the silanol groups on the surface of the silicate.  Mallick et al. reported the formation 
of amorphous Ibuprofen when it was co-ground with Kaolin (hydrated aluminum silicate) 
in a ball mill.  The amorphous complex was found to be physically stable at 40
o
C/75% 
RH for a period of 10 weeks.  The physical stability was attributed to salt formation 
involving the carboxyl group of Ibuprofen which was determined using FTIR analysis. 
Inorganic silicates provide an alternate mechanism of stabilization of amorphous API 
through salt formation potential which is in contrast to organic polymers.  Because there 
is the potential for stabilization using inorganic silicates there is the need to understand 
how salt formation of acidic drugs with inorganic silicates can be used to produce a 
physically stable amorphous phase and how the process can be scaled up to ultimately 
produce a marketable drug product.  
 
Gaps in the Literature 
 There has been some investigation in utilizing silicates to increase stability in 
amorphous solids.  One particular excipient, Neusilin US2 (Neusilin) has been used very 
successfully in the stabilization of solid amorphous drug material.  Recent literature has 
shown that Neusilin in combination with an acidic solid amorphous drug promotes phase 
stability through complex formation between Neusilin and the acidic moiety when the 
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two are ground together
 [1-3]
.  While the success of complex formation between the 
Neusilin and acidic drug has been well documented,  the details of milling process, 
stability mechanisms, or whether the amorphization process can be scaled up beyond the 
bench need to be further investigated.   
There has only been limited description of the types of mills used in these studies.  
In addition, milling conditions have not been fully described or addressed.    No optimal 
milling process has been identified to maximize the amount of amorphization in a given 
sample.  There has been no demonstration of the ability to scale up the amorphization 
process using the complex formation mechanism available with Neusilin and an acidic 
drug solid.  Without information on whether the process can be scaled up beyond bench 
top applications there is no knowing whether this process would be feasible in making a 
marketable drug product.  Because the end goal of pharmaceutical research is to develop 
a final drug product that will reach the market meeting the demands of processing and 
storage, scalability and stability are of the utmost importance.    
 
Conclusion 
 Challenges arise in the use of amorphous drugs in the form of chemical and 
physical instability which can hamper their development if not make it impossible, 
altogether.  However the advantages that can be had make the pursuit of a stable 
amorphous drug very attractive to pharmaceutical chemists.   Increasing dissolution rate 
and bioavailability of a drug are primary goals in the development of new drugs resulting 
in new methods and materials being constantly explored.  Organic excipients mixed with 
the amorphous form of a drug have been shown to help stabilize against crystallization by 
10 
 
various mechanisms.    The advantage of the use of organic polymers is that the 
amorphous solid dispersions are able to maintain the original dissolution and solubility 
advantages of the original amorphous drug material.  Several methods for the mechanism 
of stabilization of the amorphous drug material using organic polymers have been 
proposed.  These include hydrogen bonding between the excipient and drug, steric 
hindrance caused by the polymer to prevent crystallization of the amorphous material and 
an increased glass transition temperature as a result of the production of a single phase 
mixture between the polymer and amorphous drug.  The common characteristic of each 
proposed mechanism for stabilization is that they all require physical interaction between 
the amorphous material and the polymer.   
Inorganic silicates have been used in the stabilization of amorphous drug material 
recently with growing frequency.  Unlike organic polymers, inorganic silicates provide 
the possibility of stabilization of amorphous API through the mechanism of salt 
formation.  There is a definite need to better understand how salt formation of acidic 
drugs with inorganic silicates can be manipulated to produce long term physically stable 
amorphous phases.    If stabilization is accomplished then a process to scale up 
production of the amorphous form needs to be identified in order to ultimately produce a 
drug product.  The scale up of the production process has not been determined and 
requires further investigation.  While more work is currently being done in this area it has 
not yet been thoroughly explored and the reaction mechanisms between the inorganic 
excipients and amorphous drug have yet to be fully determined.   
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Chapter 2.  Formation and Stabilization of Amorphous Solids 
 
Introduction  
Improvements in solubility and dissolution rate of crystalline drug compounds by 
various methods have been shown to increase the bioavailability of the drugs
[2]
.  Because 
of this, enhancing dissolution and bioavailability is a main area of focus for 
pharmaceutical scientists in formulation development.  Use of the amorphous phase to 
improve the oral bioavailability of poorly soluble drugs is well known.  The amorphous 
form of a compound is at a higher energy state than the crystalline form, which suggests 
it will provide greater solubility and faster dissolution rates and result in higher oral 
bioavailability.  These advantages make the conversion from the crystalline form to 
amorphous desirable.  However, chemical and physical stability issues often result in 
reversion to the crystalline state or a form change and limit the use of amorphous material 
in drug development.   In spite of the difficulties in using amorphous drug material, the 
improvements in oral bioavailability make it an attractive option to try.  The key in using 
amorphous material in drug product development is the stabilization of the amorphous 
form during all processing steps as well as for long term stability or shelf life of the final 
product itself. 
A solid amorphous material is defined as having no long-range order in the 
atomic structure, while a solid material that does exhibit long-range order is defined as 
crystalline.  Most crystalline solids can be made amorphous by using a melt-quench 
technique.  This involves heating the crystalline material to where it is melted and 
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becomes a liquid, followed by rapidly cooling it, often with liquid nitrogen.  Other 
reported methods that were utilized to effect the conversion from crystalline to 
amorphous form were milling
 [1]
 and melt adsorption
 [5]
. 
  
Two milling methods that have 
been reported as successful techniques are cryo-milling under liquid nitrogen conditions 
and ball milling.   
 
 
Stabilization of Amorphous Solids  
Solid crystalline material is more thermodynamically stable than the amorphous 
form.   The amorphous form when presented the appropriate conditions will crystallize 
but not necessarily back to the original crystalline form.  Both the amorphous and 
crystalline forms have particular physical characteristics that can be either advantageous 
or detrimental depending on the intended use of the material.  This is especially true 
when developing a drug product.  The crystalline form will have a higher melting 
temperature, a slower dissolution rate and lower solubility than the amorphous form.  It is 
more stable both physically and chemically. While these traits are favorable for long term 
stability of the material they are not always desirable when using these materials for drug 
applications.  The physical traits of amorphous materials lend themselves more readily in 
drug development when attempting to maximize exposure.  Higher solubility and faster 
dissolution rates can lead to greater bioavailability when dosed
 [2, 5]
.  However, 
amorphous materials are rarely used when developing a drug product due to the 
decreased chemical and physical stability resulting in processing and storage challenges. 
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This instability can limit scale up and therefore commercialization of the drug in the 
amorphous form. 
The most common method used in stabilizing solid amorphous pharmaceuticals is 
the addition of inactive excipients that allow for the formation of amorphous solid 
dispersions.  The most frequently reported method in the literature is the use of organic 
polymers as the excipient.  The most common of these used are poly (vinyl pyrrolidone), 
polyethylene glycol, poly (methyl methacrylate) and cellulosic polymers.   The advantage 
of the use of organic polymers is that the amorphous solid dispersions are able to 
maintain the original dissolution and solubility advantages of the original amorphous 
drug material.  Several methods for the mechanism of stabilization of the amorphous drug 
material using organic polymers have been proposed.  These include hydrogen bonding 
between the excipient and drug, steric hindrance caused by the polymer to prevent 
crystallization of the amorphous material and an increased glass transition temperature as 
a result of the production of a single phase mixture between the polymer and amorphous 
drug.  The common characteristic of each proposed mechanism for stabilization is that 
they all require physical interaction between the amorphous material and the polymer.   
 
Using Silicates to Enhance Stability 
Recently investigation into using inorganic excipients in the stabilization of 
amorphous drug material has become reported in the literature with growing frequency.  
While more work is currently being done in this area, it has not yet been thoroughly 
explored and the reaction mechanisms between the inorganic excipients and amorphous 
drug have yet to be fully determined.   
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Many of the most commonly reported inorganic excipients being investigated are 
silicates.  Bahl et al.
 
reports co-grinding with six different silicates in the amorphization 
of Indomethacin
 [6]
.  These include Neusilin US2 (synthetic magnesium alumino- 
metasilicate), Veegum-F (magnesium aluminosilicate), Florite-F (calcium fluorine), 
calcium silicate, kaolin (hydrated aluminum silicate) and Aerosil-200 (fumed silica).  
Kinoshita et al. developed a  hot melt extrusion (HME) process using calcium silicate in 
order to amorphize a crystalline drug sample
[5] 
and Bogner et al. have done extensive 
work co-grinding Neusilin US2 with various pharmaceutical compounds
[1,3,4,6] 
.    
One of the more successful excipients utilized in stabilizing the amorphous form 
of a drug has been Nuesilin US2.  Gupta et al. reported 1 month of physical stability of 
the amorphous form at 40
o
C/75% Relative Humidity (RH) for drugs co-ground with 
Neusilin US2
 [4] 
.  Bahl et al. reports not only 3 months of physical stability at 40
o
C/75% 
RH of amorphous Indomethacin co-ground with Neusilin but that the Indomethacin 
ground with Neusilin was amorphized in less time than when ground with the other 
silicates used in the same study.  Silanols present on the surface of Neusilin make it a 
potential proton donor or proton acceptor due to the high hydrogen bonding potential of 
the silanols.  This lead to the suggested stabilizing mechanisms of hydrogen bonding or 
acid-base reactions between the drug and silanols  and possible ion-dipole interactions 
between the drug and metal ions at the surface of Neusilin
 
.  The same study reported the 
dependence of amorphization kinetics of Indomethacin on the weight ratio of 
Indomethacin to Neusilin used during co-grinding as well as the grinding time itself.  
Samples ground for longer periods of time resisted crystallization longer than the samples 
with shorter milling times 
[6]
.  Gupta et al. reported that carboxylic acid containing drugs 
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form an amorphous salt when milled with Neusilin.  The amorphous complex was found 
to be physically stable at 40
o
C/75% RH for a period of 4 weeks.  The physical stability 
was attributed to salt formation involving the carboxyl group of the acidic drugs 
determined by FTIR data that showed an absence of the carbonyl peaks 
[4]
.  The increased 
stability of the amorphous form and shorter milling times make Nuesilin an attractive 
candidate for further study.   
Utilizing another silicate other than Neusilin, Kinoshita et al. have reported 
producing an amorphous phase of a development drug TAS 301 when hot melt extruded 
with porous calcium silicate.  The amorphous phase produced after extrusion showed an 
improvement in oral bioavailability and was found to be physically stable for a period of 
two years at ambient conditions.  The mechanism of stability of the amorphous form was 
attributed to the melt adsorption of the drug onto the porous silicate with the possibility 
of hydrogen bonding between the drug and the silanol groups on the surface of the 
silicate 
[5]
.   
Unlike organic polymers, inorganic silicates provide the possibility of 
stabilization of amorphous API through the mechanism of salt formation.  There is a 
definite need to better understand how salt formation of acidic drugs with inorganic 
silicates can be manipulated to produce long term physically stable amorphous phases.    
If stabilization is accomplished then a process will need to be identified that can be scaled 
up to ultimately produce a drug product which is an avenue of investigation that has not 
been thoroughly explored. 
 
Analysis Techniques 
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Analysis techniques such as X-Ray Powder Diffraction (XRPD), Differential 
Scanning Calorimetry (DSC) and Solid State Nuclear Magnetic Resonance (SSNMR) aid 
in determining the difference between the two forms.  The most common use of XRPD in 
drug development is in the characterization of crystalline drug compounds.  Each 
crystalline material analyzed will have a unique diffraction pattern displaying distinctive, 
sharp peaks in the X-Ray scan.  Amorphous material will produce a broad background 
signal, also known as an amorphous halo.  This diffraction pattern has no sharp peaks 
indicating a lack of crystalline lattice structure.  However, when the crystal size is very 
small it can be difficult to determine between a truly amorphous material and the 
crystalline form.  This is further complicated by the fact that a large proportion of the 
atoms are located at or near the surface of very small crystals.  The smaller the crystal, 
the higher the surface area it has.  A decrease in structural order can be seen due to 
interfacial effects and relaxation of the surface which can distort the atomic positions.    
DSC analysis can give a more definitive answer in determining whether the 
sample is crystalline or amorphous.  The DSC curve will show at what temperatures 
endothermic and exothermic events occur within the sample as it is being heated.  If the 
sample is amorphous a glass transition, Tg, will be observed.   The transition occurs as an 
amorphous solid is being heated and is observed as a step in the baseline signal of the 
DSC curve at a temperature lower than the melting point of the crystalline form.  During 
this transition no formal phase change occurs.  An amorphous sample will become less 
viscous as the temperature increases allowing the molecules to rearrange into a crystalline 
form.  If this occurs an exothermic peak will be observed in the DSC signal which will 
then be identified as the crystallization temperature, Tc.  As the temperature increases the 
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sample will ultimately reach its melting temperature, Tm which will appear as an 
endothermic event in the DSC signal and may or may not occur at the same temperature 
as the melting point of the original crystalline material.  A melting point that is different 
from the original crystalline material indicates that the amorphous sample crystallized 
into a different form from that of the original material.   
SSNMR can detect atomic differences within a group of molecules when the only 
difference present is in the immediate chemical environment of the group of atoms in 
question.  When compared with the original crystalline material the amorphous form will 
be indicated by a chemical shift observed in the NMR spectra.  This makes it a very 
useful technique in determining the amount or percentage of amorphous material present 
in a given sample.  NMR data can also be utilized to determine the kinetics of the 
amorphization process.  When the percent of amorphous material present in the sample is 
plotted against processing or milling time a picture of the kinetics of overall amorphous 
formation emerges.  This information allows insight into the mechanism of the reaction 
especially where excipients used to increase stability are involved in the formation of the 
amorphous phase.   
Utilizing the analytical techniques available with XRPD, DSC and SSNMR 
together presents a cohesive and more comprehensive understanding of the 
amorphization and stabilization process.   
 
Conclusion 
 Increased solubility and dissolution rate are desirable characteristics inherent in 
the amorphous form of a crystalline drug.  Due to the less stable nature of amorphous 
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material a reliable method for consistently generating the amorphous form and stabilizing 
it against crystallization is needed.  Various methods have been demonstrated to produce 
the amorphous form from a crystalline drug.  Melt-quenching is a common method to 
amorphize crystalline material although does not allow for the addition of an excipient 
and therefore is more difficult to stabilize.  Cryo-milling under liquid nitrogen conditions 
and ball milling have both been shown to be reliable methods for producing amorphous 
material both with and without the addition of excipients.  An optimized method of 
milling, whether utilizing an excipient or not, still remains to be identified.  Further 
investigation into the development of a method for scaling up the production of 
amorphous material beyond the bench top is also needed. 
Previous work done with both organic and inorganic excipients has demonstrated 
promising results in the stabilization of amorphous materials.  The most commonly used 
excipients are organic polymers.  The main advantage of this method is that the 
dissolution and solubility improvements of the original amorphous drug material are 
maintained in the amorphous solid dispersions.  Stabilization is also increased with the 
addition of organic polymers with several different stabilization mechanisms proposed 
that all share a common characteristic.  Each proposed mechanism for stabilization 
requires physical interaction between the amorphous material and the polymer.  The most 
probable of the suggested mechanisms include hydrogen bonding between the excipient 
and drug, steric hindrance that prevents crystallization of the amorphous material and an 
increased glass transition temperature as a result of the production of a single phase 
mixture between the polymer and amorphous drug.   
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Inorganic silicates are being investigated more frequently as promising excipients 
because of a trend toward increased stabilization of amorphous material.  In the case of 
Neusilin, a synthetic magnesium aluminometasilicate, it has been demonstrated to aid in 
the amorphization process resulting in a higher percentage of amorphous material formed 
as opposed to processing without an excipient.  Suggested stabilizing mechanisms 
include hydrogen bonding or acid-base reactions between the drug and silanols and 
possible ion-dipole interactions between the drug and metal ions at the surface of 
Neusilin.   The production of the amorphous phase of a development drug was 
demonstrated utilizing porous calcium silicate and a hot melt extrusion process.  The 
extruded amorphous material showed an improvement in oral bioavailability and was 
found to be physically stable for a period of two years at ambient conditions.  The 
proposed mechanism of stability was a melt adsorption of the drug onto the porous 
silicate with the possible addition of hydrogen bonding between the drug and the silanol 
groups on the surface of the silicate.   
The investigation into the use of inorganic silicates with amorphous material has 
revealed a desirable advantage.  Inorganic silicates present a stabilization mechanism 
through salt formation which is not possible with organic excipients.  The manner in 
which salt formation of acidic drugs with inorganic silicates can be manipulated to 
produce long term physically stable amorphous phases requires further investigation.    
First the stabilization of the amorphous form of a crystalline drug must be accomplished.  
Once achieved a process will then need to be developed that allows for the scale up of the 
production of the stable amorphous material.  Only this will ultimately produce a 
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marketable amorphous drug product and is an area of drug development that has not yet 
been fully explored. 
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Chapter 3.  Project Background 
 
Scope of the Project 
 Previous studies have shown that the most success at stabilizing an amorphous 
drug occurred when the drug was acidic.  The stabilization is often attributed to 
interactions brought about by co-grinding between the carboxyl group of the drug and the 
excipient.  In order to better determine a mechanism for stabilization three types of drugs 
were investigated; an acidic, a basic and a neutral drug.  It has been indicated that the 
presence of an acidic group in the drug molecule may be required for a stable 
drug/excipient complex to form.  If stabilization of either the basic or neutral drug were 
to occur alternative stabilization mechanisms could be discovered and explored. 
 In designing amorphization experiments the best possible milling method first 
must be identified.  The method used must encompass the milling conditions that can 
produce Neusilin-drug complexes and the effect of the milling parameters must be 
determined.  Once the best method is identified the milling process can be optimized 
resulting in a higher yield of the amorphous phase of the sample.   The initial attempts at 
amorphization of crystalline drug were performed using a cryo-mill under liquid nitrogen 
conditions.    Ball milling was the next technique investigated in order to determine if the 
milling process could be further optimized.  All of the samples were milled both with and 
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without the addition of the excipient Neusilin.  Milling times and techniques were 
developed for optimization by analyzing milled samples at predetermined time points 
using XRPD to determine the extent of amorphization taking place.   
 Once the milling method and technique had been optimized and samples were 
found to be stable for more than a week the next step was to determine the reaction 
mechanism.   Because the formation of a complex between the drug and Neusilin is the 
key to the stabilization of the amorphous form 
13
C SSNMR analysis was used to further 
understand the mechanism of complex formation.  Samples milled under optimized 
conditions with the addition of Neusilin were taken at various time points and analyzed as 
a function of time.  The data showed the percentage of amorphous conversion over 
milling time as well as an indication of the reaction mechanism for complex formation. 
 The next step was to identify a scalable process that would result in the same 
drug/Neusilin complex formation.  This process would be used demonstrate the 
feasibility of scaling up the production of the amorphous Neusilin-drug complexes.  Hot 
Melt Extrusion (HME) was found to produce the same amorphous drug/Neusilin 
complexes as milling but with a higher percent of amorphous conversion.  HME is a 
scalable process that can be used at the commercial level.  The process of complex 
formation was not only scalable but was also improved upon.   
 Once the HME process was shown to be successful investigation of the stability 
of the amorphous drug/Neusilin complex was begun.  The dissolution profile of the HME 
product was determined concurrently with the stability study of the samples.  The HME 
complex was found to have an improved dissolution profile over the crystalline drug as 
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well as the milled drug/Neusilin complex.  Additionally it was found to be stable for a 
longer period of time than the milled samples. 
 The final step in the process was to determine the feasibility of formulating a drug 
product containing amorphous drug/Neusilin complexes.  Tablets were made with the 
HME material using the same formulation recipe as is used in the commercially available 
tablets containing crystalline drug.  An improvement in the dissolution profile of the 
tablet formulated using the amorphous HME material when compared to the tablet made 
with crystalline material would indicate the positive viability of using an amorphous drug 
complex in drug product development.  The tablet made with HME amorphous material 
was found to have the same dissolution profile as the tablet made with crystalline 
material.  An investigation into the excipients used found that Magnesium Stearate was 
causing crystallization of the amorphous complex when added to the tablet formulation.  
An excipient study was initiated to identify alternative excipients with heightened 
sensitivity toward preventing crystallization. 
 
Experimental 
 
Materials   
Sulindac ((Z)-5-fluoro-2-methyl-1-[[p-(methylsulfinyl)phenyl]methylene]-1H-
indene-3-acetic acid), an acidic non-steroidal anti inflammatory drug, was purchased 
from Toronto Research Chemicals (North York, Ontario) and was used as-received.  The 
chemical structure of Sulindac is shown in Figure 1.  Griseofulvin (2S,6'R)- 7-chloro- 
2',4,6-trimethoxy- 6'-methyl- 3H,4'H-spiro [1-benzofuran- 2,1'-cyclohex[2]ene]- 3,4'-
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dione), a neutral oral anti-fungal drug was purchased from Sigma-Aldrich and used as-
received. The chemical structure of Griseofulvin is shown in Figure 2.  Astemizole 1-[(4-
fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidyl]benzoimidazol-2-
amine, a free-base antihistamine drug was purchased from Sigma-Aldrich.  The chemical 
structure of Astemizole is shown in Figure 3.  Neusilin US2 synthetic magnesium 
aluminometasilicate sample was obtained as a gift from Fuji Chemicals (Englewood, NJ).  
The chemical structure of Neusilin is shown in figure 4.  Pyrimethamine 5-(4-
chlorophenyl)-6-ethyl- 2,4-pyrimidinediamine, a free-base is used as an antimalarial drug 
for both the prevention and treatment of malaria.  The Pyrimethamine used was 
purchased from MP Biomedicals.  The chemical structure of Pyrimethamine is shown in 
figure 5. 
 
 
 
 
 
Figure 1.  Chemical structure of Sulindac 
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Figure 2.  Chemical structure of Griseofulvin 
 
 
 
 
 
 
 
 
Figure 3.  Chemical structure of Astemizole 
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Figure 4. Chemical structure of Neusilin 
 
 
 
 
 
Figure 5.  Chemical Structure of Pyrimethamine 
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Methods 
 
Preparation of melt quenched amorphous sample 
The amorphous phase of Sulindac was generated by melt quenching.  About 
500mgs of Sulindac was held isothermally at 190
o
C (above its melting point) for 2 
minutes in a glass vial.  The vial was then immersed in liquid nitrogen to produce the 
amorphous phase of Sulindac.  The amorphous material was recovered from the vial and 
was gently ground with a mortar and pestle to reduce its particle size.  The ground 
amorphous material was stored over desiccant in a closed container. 
 
 
Milling 
A Retsch Ball Mill model #MM301 was used for room temperature milling with 
and without Neusilin.  The samples to be milled were placed in a 25mL chamber with 
metal grinding balls at room temperature.  The vibration frequency of the mill was set at 
20Hz for all experiments.  The samples were milled for varying lengths of time between 
10 and 60 minutes.  At pre-determined times points the solid sample was removed from 
the mill for further characterization to understand the kinetics of the mechanochemical 
reaction.  Milling was continued until the sample was ascertained to be completely 
amorphous using X-ray powder diffraction and 
13
C solid state NMR.   
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A Spex SamplePrep Freezer Mill model #6770 was used to mill samples with and 
without Neusilin at liquid nitrogen temperatures.  The milling time was set at 10 minute 
intervals.  At the end of each interval the liquid nitrogen bath was refilled.  The samples 
were milled for varying total times between 10 and 60 minutes in 10 minute intervals.  At 
pre-determined time points the solid sample was removed from the mill for further 
characterization to understand the kinetics of the mechanochemical reaction.  Milling was 
continued until the sample was ascertained to be completely amorphous using X-ray 
powder diffraction. 
 
 
X-Ray Powder Diffraction (XRPD) 
The diffractometer (PANanlytical X’pert, Philips) was equipped with a CuK 
source ( = 1.54056 Å) operating at a tube load of 45 kV and 40mA. The divergence slit 
size was 1/4, while the receiving slit and the detector slit, were 5.0mm, and 0.1mm 
respectively. Small amount of sample was loaded onto Si 510 zero-background sample 
holder and scanned between 3 and 40 (2) with a step size of 0.008 and a step time of 
15.2 s/step in the continuous mode. Data was collected by a high-resolution sealed 
proportional detector.  The Si (111) with a diffraction peak at 28.44 2 was used as a 
standard to calibrate the instrument. 
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Differential scanning calorimetry (DSC) and Thermogravimetric analysis (TGA) 
DSC measurements were conducted in crimped Aluminum pans using a Q1000 
(TA Instruments, Newcastle, DE) unit under 50mL/min N2 purge. 2 to 3 mg samples 
were tested each time. Standard DSC scan using a heating rate of 10C /min and 
modulated DSC scan using a heating rate of 5C/min with modulation amplitude of 0.5 C 
within a period of 40 s were used.  Indium was used as the calibration standard. 
TGA measurements were conducted in Aluminum pans using a Q500 (TA Instruments, 
Newcastle, DE) unit under 50mL/min N2 purge.  A heating rate of 10C/min was used for 
all TGA runs.   
 
 
 
Solid State Nuclear Magnetic Resonance (SSNMR) 
All SSNMR measurements were conducted using a Bruker DSX spectrometer 
operating at a 
1
H resonance frequency of 600MHz.  A Bruker 4-mm double resonance 
magic angle spinning (MAS) probe head was used to record all NMR data.  
13
C NMR 
spectra were recorded using routine cross polarization sequence with sample spinning at 
14 kHz.  512 to 1024 transients were collected for each sample for signal to noise 
averaging.  
1
H 90° pulse length of 2.5 s and a cross polarization contact time of 2 ms 
were employed.  
1
H decoupling was achieved with a spinal 64 sequence using a pulse 
length of 5 s.  A recycle delay of 10 seconds was used for all samples.  A total 
suppression of spinning sidebands (TOSS) sequence was appended to the CP sequence to 
32 
 
achieve a spectrum free of spinning sidebands.  Natural abundance glycine with the 
carbonyl peak at 176.03ppm was used as the chemical shift reference. 
 
 
 
Hot Melt Extrusion (HME) 
The purpose of the HME experiments was to determine the scalability of 
producing stable Neusilin-drug complexes.  Blends of Neusilin-drug in a 1:1 and 2:1 by 
weight ratios were extruded using a Prism PharmaLab 16mm Twin Screw Extruder.  The 
extruder temperature was held at 200°C, the screw speed was 50 rpm, and the volumetric 
feed rate was set at 5%.  Each run processed a total of 100g of material.   
 
 
 
Powder Dissolution 
Powder dissolution data were generated using a 6-channel pION μ-Diss Profiler 
(pION Inc., Woburn, MA) apparatus in 0.1 N HCl media with a stirring speed of 100 rpm 
at ambient conditions.  The dissolution rate profiles of Sulindac and Sulindac-Neusilin 
complexes in the medium were monitored using an in-line UV detector employing fiber 
optic cables.  The concentration profiles were calculated using a standard curve 
determined using a DMSO stock solution of the drug.  Each sample was analyzed in 
triplicate and the average concentrations and standard deviations are reported.  For sake 
of clarity not all data points collected are shown.  
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Stability Analysis 
Samples ball-milled with and without Nuesilin and HME samples were stored in 
stability chambers at 25
o
C/60% RH and 40
o
C/75% RH conditions.  Approximately 25mg 
of each sample was weighed into glass vials using a separate vial for each timepoint.  
Vials were closed for storage.  Samples were assayed by XRPD and HPLC for each time 
point to determine both chemical and physical stability. 
 
 
Tablet Formation 
 Tablets were made on a Carver Press using a direct compression method.  The 
tablets were formulated using a blend of  80%  Hot Melt Extruded 1:1 ratio of  Sulindac 
to Neusilin, 9.5% Avicel PH 102, 9.5% Starch 1500, and 1% Magnesium Stearate.  Each 
tablet had a total weight of 500mg.  
 
 
Conclusion 
 Both cryo-milling and ball milling have been identified in various studies as 
reliable methods to produce the amorphous form of a drug when milled with and without 
excipients.  The addition of excipients has been found to increase the likelihood of the 
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transition to the amorphous form. Addition of excipients, such as inorganic silicates 
like Neusilin, has also been demonstrated to assist in the stabilization of the amorphous 
form.  The most likely mechanisms for stabilization of the amorphous drug/excipient 
complexes formed would best be determined by analysis using 
13
CSSNMR.  The stability 
of the amorphous drug/Neusilin complex is attributed to hydrogen bonding and/or an 
acid-base reaction between Silanol groups on the surface of Neusilin and the acid moiety 
in Sulindac which could be clarified with the use of 
13
CSSNMR analysis.    
 DSC and TGA analysis would identify the glass transition and melt temperature 
of the amorphous material generated by ball milling.  Comparison of the glass transition 
temperature with the relative milling temperature could either prove or disprove the idea 
that milling below or near the glass transition temperature results in a higher rate of 
amorphization.   
XRPD is an invaluable tool in determining whether amorphization has occurred in 
a milled or HME sample.  With a relatively quick analysis run, about 15 minutes, it can 
be determined whether a sample has become amorphous or not.  A scan showing an 
amorphous halo with no crystalline peaks is the ideal outcome when attempting the 
amorphization of a crystalline compound.  When peaks are still observed growing out of 
the halo, optimized milling or processing times can be developed to further the 
amorphization process allowing for a more reliable method for amorphization.  On the 
other hand, when no amorphous halo is observed in the scan and crystalline peaks remain 
after substantial milling times XRPD can definitively determine that a sample is not 
going to amorphize and allow the researcher to move on. 
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 The amorphization process investigated worked very well using bench top mills 
however not all bench top processes can be scaled up.  If the process cannot be scaled up 
then it cannot be used for any commercial applications rendering it useless for 
development.  Due to the results of the stability studies of the milled material it was 
determined that temperature during milling has a significant effect on the outcome of 
stability.  Hot Melt Extrusion (HME) therefore was identified as a possible means to 
scale up production of the Sulindac/Neusilin complex.  HME as a process has the 
possibility of amorphizing a greater percentage of the crystalline drug and may result in 
greater long term stability of the drug/Neusilin complex.  This would result in amorphous 
samples of superior quality to what the ball mill produced and would identify HME as a 
viable method to scale up production enough to enable further development of the 
amorphous complex. 
 The formation of a useful drug product is the end goal for Pharmaceutical 
development.  To this end a drug product containing the amorphous material would need 
to be compared to the commercially available drug product.  For direct comparison 
tablets would be formulated containing the amorphous material using the same recipe as 
the commercially available tablet containing crystalline material.  Dissolution 
experiments would clearly demonstrate any improvement in solubility and dissolution 
rate of the amorphous drug product over that of the crystalline drug product.  Care would 
need to be taken in order to prevent crystallization of the amorphous form by the addition 
of excipients or by the pressure induced by the press to form the tablets. 
Determining the stability of the amorphous samples generated is a key component 
for the development of a drug product using amorphous material.  Samples stored in 
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stability chambers at accelerated conditions (40
o
C/75% RH) allow the samples to be 
stored for a shorter amount of time than they would otherwise be if held at room 
temperature conditions.  This allows for a faster determination of the long term stability 
of the samples and drug product saving time during the investigation process.     
The development of a drug product using the amorphous form of a crystalline 
drug promises to provide improvements upon the original drug product.  It is known that 
an improvement in the dissolution can relate to an improvement in bioavailability.  If the 
bioavailability were to show the expected improvement in the amorphous drug product, 
then drug load in the new product could be lower.  This has the added benefit of lowering 
the production costs of the drug by lowering the amount of drug produced while keeping 
the efficacy of the drug product the same. 
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Chapter 4.  Griseofulvin 
 
Introduction 
In formulation development enhancing dissolution and bioavailability is a main 
area of focus for pharmaceutical scientists.   Improvements achieved in these areas by 
various methods have been shown to increase the bioavailability of crystalline drug 
compounds 
[2]
.  Amorphization of crystalline drug compound is a proven method and as 
such use of the amorphous phase to improve the oral bioavailability of poorly soluble 
drugs is well known.  The main drawback to pursuing development of the amorphous 
form is the decrease in chemical and physical stability found after amorphization.   
The higher energy state of the amorphous form of a crystalline compound 
suggests it will afford greater solubility and faster dissolution rates resulting in higher 
oral bioavailability.  While these advantages make the conversion from the crystalline 
form to amorphous appear favorable chemical and physical stability issues do exist. The 
challenges to the stability of the amorphous form often result in reversion to the 
crystalline state or a form change.  These issues are the main limiting factor in the use of 
amorphous material for drug development.  In fact, amorphous materials are rarely used 
when developing a drug product due to processing and storage challenges caused by the 
decrease in chemical and physical stability. These issues can limit scale up and therefore 
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commercialization of the drug in the amorphous form.  In spite of the challenges posed, 
promise of improvements in oral bioavailability make amorphization of a poorly soluble 
crystalline drug an attractive area for development.  The main point in developing 
amorphous drug material for product development is the stabilization of the amorphous 
form during all processing steps, long term stability and shelf life of the final product. 
 The most successful studies aimed at the stabilization of an amorphous drug were 
achieved with an acidic drug combined with an inorganic excipient.  The stabilization has 
been attributed to interactions between the carboxyl group of the drug and reactive sites 
on the excipient brought about by co-grinding, although no definitive explanation of the 
reaction mechanism has been developed.  In an effort to establish a mechanism for 
stabilization three types of drugs were investigated; an acidic, a basic and a neutral drug.  
It has been suggested that the presence of an acidic group in the drug molecule may be 
required for a stable drug/excipient complex to form.  If stabilization of either the basic or 
neutral drug were to occur alternative stabilization mechanisms could be determined and 
utilized. 
This study investigated the amorphization and stabilization of a neutral drug 
compound.  Griseofulvin is an orally administered anti-fungal drug marketed by Glaxo 
Laboratories as Grisovin.  It is used in both humans and animals to treat fungal infections 
in the nails and skin, primarily ringworm.  It has a melt temperature of 220
o
C with the 
onset temperature of glass transition at 48
o
C.  Griseofulvin was chosen for investigation 
based on the structure as a neutral compound and that it is readily available for purchase. 
 
Methods 
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 Milling 
A Retsch Ball Mill model #MM301 was used for room temperature milling with 
and without Neusilin.  The samples to be milled were placed in a 25mL chamber with 
metal grinding balls at room temperature.  The vibration frequency of the mill was set at 
20Hz for all experiments.  The samples were milled for varying lengths of time between 
10 and 60 minutes.  At pre-determined times points the solid sample was removed from 
the mill for further characterization to understand the kinetics of the mechanochemical 
reaction.  Milling was continued until the sample was ascertained to be completely 
amorphous using X-ray powder diffraction and 
13
C solid state NMR.   
A Spex SamplePrep Freezer Mill model #6770 was used to mill samples with and 
without Neusilin at liquid nitrogen temperatures.  The milling time was set at 10 minute 
intervals.  At the end of each interval the liquid nitrogen bath was refilled.  The samples 
were milled for varying total times between 10 and 60 minutes in 10 minute intervals.  At 
pre-determined time points the solid sample was removed from the mill for further 
characterization to understand the kinetics of the mechanochemical reaction.  Milling was 
continued until the sample was ascertained to be completely amorphous using X-ray 
powder diffraction. 
 
 
X-Ray Powder Diffraction (XRPD) 
The diffractometer (PANanlytical X’pert, Philips) was equipped with a CuK 
source ( = 1.54056 Å) operating at a tube load of 45 kV and 40mA. The divergence slit 
size was 1/4, while the receiving slit and the detector slit, were 5.0mm, and 0.1mm 
41 
 
respectively. Small amount of sample was loaded onto Si 510 zero-background sample 
holder and scanned between 3 and 40 (2) with a step size of 0.008 and a step time of 
15.2 s/step in the continuous mode. Data was collected by a high-resolution sealed 
proportional detector.  The Si (111) with a diffraction peak at 28.44 2 was used as a 
standard to calibrate the instrument. 
 
Cryo-milling 
 Cryo-milling was the initial milling technique used to attempt the conversion of  
griseofulvin from the crystalline to the amorphous form.  Griseofulvin was cryo-milled 
with no excipients for a total of 60 minutes.  Samples were removed at 10 minutes and 60 
minutes for XRPD analysis.  When compared with the baseline scan of un-milled 
crystalline Griseofulvin it can be seen that over time some amorphization does occur.  
The baseline scan shows well defined, sharp peaks that are indicative of a crystalline 
structure.  After 60 minutes of milling certain changes can be observed in those sharp 
peaks that were present in the base line scan.  All have decreased in intensity and at some 
points they have disappeared entirely into the amorphous halo.  An example is the peak 
that appears at 18.02
o
 2 Theta in the baseline scan.  In the sample taken after 10 minutes 
of milling this peak is observed to be diminishing in intensity.  The same peak observed 
in the sample analyzed after 60 minutes of milling is lost in the amorphous halo forming 
in between the still observable peaks.   Although amorphization is beginning to occur it is 
not complete after 60 minutes of cryo-milling as shown in figure 1.    
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Figure 1.  Baseline XRPD scan of Griseofulvin compared with XRPD scans of 
Griseofulvin cryo-milled at times of 10 and 60 minutes.  No amorphous conversion 
observed. 
 
 
Because cryo-milling Griseofulvin without excipients for 60 minutes failed to 
generate the amorphous form the same milling procedure was repeated but with the 
addition of Neusilin as an excipient in a 1 to 1 ratio of drug to Neusilin for a total volume 
of 1 gram of material.  It has been shown in literature that co-grinding crystalline drug 
material with a silicate can increase amorphization of the drug
 [1]
.   The first sample taken 
at 35 minutes for XRPD analysis showed a greater degree of amorphous conversion than 
the Griseofulvin milled alone for 60 minutes.  While the peak at 18.02
o
 2 Theta has 
disappeared completely, some crystalline peaks were still observed.  A second sample 
was analyzed after 50 minutes of milling.  The conversion to the amorphous form was 
found to be complete with no sharp peaks to indicate crystallinity observed within the 
amorphous halo as shown in figure 2.    
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Figure 2.  Griseofulvin and Neusilin in a 1:1 ratio cryo-milled for 35 and 50 
minutes.  Amorphous conversion is complete at 50 minutes. 
 
 
 
 
After generation of the amorphous form of Griseofulvin was achieved by co-
grinding with Neusilin, samples were taken and placed in two separate stability 
chambers.  The storage conditions were 25
o
C/65% Relative Humidity (RH) and at 
45
o
C/75% RH.  After 24 hours samples were removed and analyzed using XRPD.  
Crystallization can be observed in both samples regardless of storage conditions.  When 
compared to the baseline scan of un-milled crystalline Griseofulvin it is clear the 
amorphous material is crystallizing back to the original crystalline form as shown in 
figure 3.   Although the addition of a silicate as an excipient did allow for the 
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amorphization of Griseofulvin to occur it did not stabilize the amorphous form against 
crystallization. 
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Figure 3.  XRPD scan of 24 hour stability samples 1:1 Griseofulvin:Neusilin co-
ground using cryo-mill.  Storage conditions are 25
o
C/65% RH and 45
o
C/75% RH.   
 
 
 
 
Ball Milling 
 Although amorphization was observed when Griseofulvin was cryo-milled 
with Neusilin the amorphous form was found to have crystallized within 24 hours and 
was therefore not stabilized.  While it has been reported that amorphization occurs more 
easily when milling is performed at lower temperatures 
[2]
 it was decided to repeat the 
cryo-milling experiments using a ball mill where the milling temperature would be 
higher.  It has been reported that the amorphous form of a drug compound can be 
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stabilized when it undergoes a melt-adsorption process with an excipient 
[3]
, something 
that would not occur under liquid Nitrogen conditions but may be induced at the elevated 
temperatures associated with ball milling.  
Crystalline Griseofulvin was ball milled without an excipient for a total time of 60 
minutes with samples removed at 40, 50 and 60 minutes for XRPD analysis.  When 
compared to the baseline scan of un-milled crystalline Griseofulvin no amorphous 
conversion was observed at any time point.  In fact, there is no indication of even partial 
amorphization.  The XRPD data is identical for each time point and the baseline scan as 
shown in figure 4. 
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Figure 4.  Comparison of baseline XRPD scan of crystalline Griseofulvin to 
samples ball milled at 40, 50 and 60 minutes without excipient. 
 
 
The ball milling experiment was repeated under the same conditions using 
crystalline Griseofulvin with Neusilin as an excipient at a ratio of 1 to 1, drug to 
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excipient.   Milling was allowed to continue for 60 minutes with no interruptions to take 
samples in order to ensure the increase of temperature needed for a melt-adsorption 
process to occur.  After 60 minutes a sample was taken of the milled material for XRPD 
analysis.  A high degree of amorphization was observed to have occurred.  There was the 
hint of a peak in the amorphous halo at 16.76
o
 2 Theta which corresponds to an observed 
peak in the baseline scan of crystalline Griseofulvin as shown in figure 5. 
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Figure 5.  Comparison of XRPD scans of crystalline Griseofulvin and amorphous 
Griseofulvin:Neusilin in a 1:1 ratio ball milled for 60 minutes. 
 
 
 
 The milled amorphous material was divided with equal portions put in separate 
stability chambers at conditions of 25
o
C/65% RH and 45
o
C/75% RH.  After 24 hours 
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samples were taken and analyzed using XRPD.  Crystalline peaks can be seen growing in 
the amorphous halo after 24 hours at both storage conditions.  The addition of Neusilin 
aided in the amorphization of the crystalline material but stabilization was not achieved 
as shown in figure 6. 
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Figure 6.  XRPD scans of 24 hour stability samples of ball milled Griseofulvin with 
Neusilin in a 1 to 1 drug to excipient ratio stored at 25
o
C/65% RH and 45
o
C/75% RH.  
Crystallization is observed in the samples. 
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Conclusion 
 In the griseofulvin samples milled without excipient a greater degree of 
amorphization was observed for the cryo-milling technique as compared to the ball 
milling technique.  This finding correlates to a study conducted by Descamps, et. al, that 
milling at a lower temperature results in an easier amorphization process because the 
transformation takes place below the glass transition temperature (Tg) of the crystalline 
material.  It is suggested that introduction of defects in the crystalline structure during the 
milling process induces progressive destabilization.  When performed below the glass 
transition temperature an amorphous solid is formed
 [2]
.   Under liquid Nitrogen 
conditions the cryo-milling process temperature was well below the glass transition 
temperature of griseofulvin.  This would explain the higher degree of amorphization seen 
in the cryo-milled samples that contained no excipient when compared to the samples 
ball milled with no excipient.  When performed above the glass transition temperature it 
is predicted that the crystalline material will melt to a metastable liquid phase which 
would give the molecule enough freedom of motion to re-form into a crystalline 
structure.   
The temperature increase during ball milling, while not measured is assumed to 
be higher than the glass transition temperature.  Because the XRPD data for the 
griseofulvin ball milled without excipient shows no signs of amorphization it would seem 
this to be a safe assumption.  This would also explain the high degree of amorphization 
observed in the samples ball milled with excipient because as Kinoshita et. al, reported, 
amorphization can occur in the presence of an excipient through a melt-adsorption 
process that can occur during processing 
[3]
.   
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However, although the amorphization process is greatly enhanced with the 
addition of an excipient during ball milling it does not stabilize the amorphous form 
against crystallization.  The rapid crystallization of the samples indicates that there is no 
reaction occurring between the drug and the excipient which would interfere with the 
crystallization process.  The initial samples taken directly after ball milling may appear 
amorphous because a portion of the griseofulvin molecules are still in the metastable 
liquid state adsorbed on the surface of the excipient.  As the sample rests it is possible 
that the excipient is not presenting enough steric hindrance to the amorphous form to 
prevent the molecules from reorganizing themselves into a crystalline structure.  The lack 
of stability of the amorphous form of griseofulvin when co-ground with an excipient 
indicates that pursuit of the development of the amorphous form of a neutral drug 
compound would prove difficult and probably not feasible from an economic standpoint. 
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Chapter 5.  Astemizole and Pyrimethamine 
 
Introduction 
The higher energy state of the amorphous form of a crystalline compound 
suggests it will provide improvements over the less soluble crystalline from.  This 
includes greater solubility and faster dissolution rates which can result in higher oral 
bioavailability than is observed in the crystalline drug.  Use of the amorphous phase to 
improve the oral bioavailability of poorly soluble crystalline drugs is well known.  
During development of a drug product these types of improvements are highly sought 
after and developed by pharmaceutical scientists as increased bioavailability can be used 
to enhance the performance of the final drug product.     
While the advantages of increased solubility and dissolution make the conversion 
from the crystalline form to amorphous appear favorable, chemical and physical stability 
issues do exist. The challenges to the stability of the amorphous form often result in a 
form change or reversion to the crystalline state.  The challenges to stability are the main 
limiting factor in the use of amorphous material for drug development.  In fact, 
amorphous materials are only rarely used when developing a drug product due to 
processing and storage challenges caused by the decrease in chemical and physical 
stability.  The areas that require the most attention in developing amorphous drug 
material for product development is the stabilization of the amorphous form during all 
processing steps, long term stability and shelf life of the final product.  Although 
stabilization poses a challenging problem, the promise of improvements in oral 
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bioavailability make amorphization of a poorly soluble crystalline drug an attractive area 
for development.   
 Studies utilizing an acidic drug combined with an inorganic excipient 
demonstrated the most success at stabilization of an amorphous drug.  The stabilization 
mechanism has been attributed to interactions between the carboxyl group of the drug 
and reactive sites on the excipient brought about by co-grinding.  A mechanism for 
stabilization still needs to be established.  Comparing amorphization and stabilization 
using three types of drugs; an acidic, a basic and a neutral drug will clarify by what 
mechanism stabilization occurs.  It has been suggested that the presence of an acidic 
group in the drug molecule may be required for a stable drug/excipient complex to form.  
If stabilization of either the basic or neutral drug were to occur alternative stabilization 
mechanisms could be determined and utilized. 
This study investigated the amorphization and stabilization of two basic drug 
compounds.  Both astemizole and pyrimethamine were investigated due to limited 
availability of astemizole.  At the conclusion of the cryo-milling experiments it was 
discovered that astemizole was no longer available for purchase.  This may be caused by 
the fact that it has been withdrawn from the market due to rare but potentially fatal side 
effects. 
Astemizole was a second generation antihistamine marketed under the brand 
name Hismanal.  It has a melt temperature of 174
o
C with the onset temperature of glass 
transition at 45
o
C.  This compound was chosen for this study based on the structure as a 
basic compound and the assumption that it would be readily available.   
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Pyrimethamine is marketed under the brand name Daraprim and is used to treat 
protozoal infections.   It is also used for both the treatment and prevention of malaria and 
can be used in combination with Sulfadiazine for the treatment of toxoplasma gondii 
infections in immunocompromised patients, such as HIV-positive individuals.  It has a 
melt temperature of 233
o
C.  Glass transition onset temperature was not measured.   This 
compound was chosen for this study based on the structure as a basic compound and that 
it is readily available for purchase. 
 
Methods 
 Milling 
A Retsch Ball Mill model #MM301 was used for room temperature milling with 
and without Neusilin.  The samples to be milled were placed in a 25mL chamber with 
metal grinding balls at room temperature.  The vibration frequency of the mill was set at 
20Hz for all experiments.  The samples were milled for varying lengths of time between 
10 and 60 minutes.  At pre-determined times points the solid sample was removed from 
the mill for further characterization to understand the kinetics of the mechanochemical 
reaction.  Milling was continued until the sample was ascertained to be completely 
amorphous using X-ray powder diffraction and 
13
C solid state NMR.   
A Spex SamplePrep Freezer Mill model #6770 was used to mill samples with and 
without Neusilin at liquid nitrogen temperatures.  The milling time was set at 10 minute 
intervals.  At the end of each interval the liquid nitrogen bath was refilled.  The samples 
were milled for varying total times between 10 and 60 minutes in 10 minute intervals.  At 
pre-determined time points the solid sample was removed from the mill for further 
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characterization to understand the kinetics of the mechanochemical reaction.  Milling was 
continued until the sample was ascertained to be completely amorphous using X-ray 
powder diffraction. 
 
 
X-Ray Powder Diffraction (XRPD) 
The diffractometer (PANanlytical X’pert, Philips) was equipped with a CuK 
source ( = 1.54056 Å) operating at a tube load of 45 kV and 40mA. The divergence slit 
size was 1/4, while the receiving slit and the detector slit, were 5.0mm, and 0.1mm 
respectively. Small amount of sample was loaded onto Si 510 zero-background sample 
holder and scanned between 3 and 40 (2) with a step size of 0.008 and a step time of 
15.2 s/step in the continuous mode. Data was collected by a high-resolution sealed 
proportional detector.  The Si (111) with a diffraction peak at 28.44 2 was used as a 
standard to calibrate the instrument. 
 
 
Astemizole and Cryo-Milling 
 The initial milling technique used to attempt the conversion of Astemizole from 
the crystalline to amorphous form was cryo-milling.  An XRPD baseline analysis of 
crystalline astemizole was taken to demonstrate crystallinity prior to milling.  The 
baseline scan shows well defined, sharp peaks that are indicative of a crystalline 
structure.  Astemizole was milled with no excipients for a total of 60 minutes.  Samples 
were removed at 40, 50 and 60 minutes for XRPD analysis.  When compared with the 
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baseline scan of un-milled crystalline astemizole it was observed that no amorphization 
had taken place.  The data taken for the baseline scan appears identical to the data 
obtained at each time point as shown in figure 1. 
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Figure 1.  XRPD data for un-milled crystalline Astemizole and samples cryo 
milled for 40, 50 and 60 minutes.  No amorphous conversion is observed. 
 
 
 
Astemizole was then cryo-milled with Neusilin in a 1 to 1 drug to excipient ratio 
with a total volume of 1 gram of material for a total time of 60 minutes.  This has been 
reported in literature to be a reliable method for increasing the probability of amorphous 
conversion 
[1]
 and had been demonstrated in previous experiments using Griseofulvin.  
Samples were not removed for analysis over the course of the milling process due to the 
lack of amorphous conversion after 60 minutes of milling without Neusilin.  The XRPD 
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analysis done after 60 minutes of milling with Neusilin shows that a high degree of 
amorphization has taken place.    See figure 2. 
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Figure 2.  XRPD data of astemizole cryo-milled for 60 minutes with Neusilin in a 
1 to 1 drug to excipient ratio.  Complete amorphization appears to have occurred. 
 
 
Once generation of the amorphous form of astemizole had been achieved by co-
grinding with Neusilin, the milled material was divided into equal portions and placed in 
two separate stability chambers.  The storage conditions were 25
o
C/65% Relative 
Humidity (RH) and at 40
o
C/75% RH.  After 24 hours samples were removed and 
analyzed using XRPD.  Crystallization can be observed in both samples regardless of 
storage conditions.  When compared to the baseline scan of un-milled crystalline 
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astemizole it is apparent that the amorphous material is crystallizing back to the original 
crystalline form as shown in figure 3. 
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Figure 3.  XRPD analysis of un-milled astemizole compared with 24 hour 
stability samples of astemizole cryo-milled with Neusilin in a 1 to 1 drug to 
excipient ratio stored at 25
o
C/65%RH and 40
o
C/75% RH.  The amorphous form 
has crystallized to the original crystalline form. 
 
 
 
 
Pyrimethamine and Ball Milling 
 Pyrimethamine was ball milled without excipient for a total of 65 minutes with a 
sample removed at 35 minutes for XRPD analysis.    An XRPD baseline analysis of 
crystalline pyrimethamine was taken to demonstrate crystallinity prior to milling.  The 
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baseline scan shows well defined, sharp peaks that are indicative of a crystalline 
structure.  After 35 minutes of ball milling the XRPD scan shows a decrease in the 
intensity and sharpness of the crystalline peaks.  This trend was observed to have 
continued in the sample analyzed after 65 minutes of milling.  The broadening of the 
peaks and the decrease in intensity indicates some amorphization is occurring in the 
sample but is not complete after an hour as shown in figure 4. 
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Figure 4.  XRPD analysis of un-milled crystalline pyrimethamine compared to ball milled 
samples without excipient at 35 and 65 minutes.  Some conversion to the amorphous 
form has occurred. 
 
 
 The ball milling experiment was repeated with Neusilin added to the 
pyrimethamine to be co-ground in a 1 to 1 ratio of excipient to drug.  One sample was 
removed after 35 minutes of milling for XRPD analysis with a second sample being 
analyzed after 65 minutes of milling.  It can be observed that there is a greater degree of 
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amorphicity in the samples milled with Neusilin than without even after milling for only 
35 minutes.  However, complete amorphization has not taken place as indicated by the 
presence of crystalline peaks at 12
o
 and 18
o
 2 Theta.  These peaks directly correspond to 
the two peaks with highest intensity observed in the crystalline pyrimethamine baseline 
XRPD data.  This indicates that the milled samples contain crystalline material that is of 
the same form as the original crystalline form prior to milling and no form conversion has 
taken place.  Because full amorphous conversion could not be achieved no samples were 
placed on stability for further analysis as shown in figure 5. 
 
2 Theta
0 10 20 30 40
In
te
n
s
it
y
 (
a
rb
it
ra
ry
 u
n
it
s
)
35 min mill
   65 min mill
Baseline
    
Figure 5.  Comparison of XRPD data of crystalline pyrimethamine prior to milling and 
pyrimethamine co-ground with Neusilin in a 1 to 1 ratio for 35 and 65 minutes.  
Complete amorphization has not occurred. 
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Conclusion 
The astemizole samples cryo-milled without excipient demonstrated a much 
lesser degree of amorphization than was observed for the samples cryo-milled with 
Neusilin.  The samples milled with Neusilin appeared to have undergone complete 
amorphous conversion.   A greater degree of amorphization is also observed for the 
pyrimethamine co-ground with Neusilin using the ball mill.   The greater degree of 
amorphization of a crystalline drug when co-ground with a silicate excipient supports the 
findings of Bahl et. al. 
[1]
       
When the two milling techniques are compared it is obvious that a greater degree 
of amorphization does occur at the lower temperature provided by the cryo-milling under 
liquid nitrogen conditions.  This observation agrees with a study conducted by Descamps, 
et. al, that milling at a lower temperature results in a higher degree of  amorphous 
conversion because the transformation takes place below the glass transition temperature 
(Tg) of the crystalline material.  It is suggested that introduction of defects in the 
crystalline structure during the milling process induces progressive destabilization and 
when this process is performed below the glass transition temperature an amorphous solid 
is formed
 [2]
.   The cryo-milling process performed under liquid nitrogen conditions was 
conducted at a temperature well below that of the glass transition temperature of 
astemizole.  This would explain the higher degree of amorphization seen in the cryo-
milled samples that contained excipient when compared to the samples ball milled with 
excipient.   
When performed above the glass transition temperature it is predicted that the 
crystalline material will melt to a metastable liquid phase which would give the molecule 
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enough freedom of motion to re-form into a crystalline structure.  The temperature 
increase during ball milling, while not measured is assumed to be higher than the glass 
transition temperature but lower than the melting temperature.  Because the XRPD data 
for the pyrimethamine ball milled without excipient shows no signs of amorphization or 
form change it would seem this to be a safe assumption.  However, because complete 
amorphization did not occur in the samples ball milled with Neusilin which were shown 
to still contain detectable amounts of crystalline material, the metastable liquid phase of 
pyrimethamine was not achieved.  Without a melt occurring during milling the melt 
adsorption process described by Kinoshita et. al, as a way to amorphize crystalline 
material would not apply 
[3]
.  This also helps explain why complete amorphization did not 
occur in the time allotted for the milling process.  Possibly if the material were milled for 
a much longer time allowing for a greater rise in temperature a melt might occur inducing 
the melt-adsorption process and complete amorphization of the sample. 
While the amorphization process is demonstrated to be greatly enhanced by the 
addition of an excipient during ball milling it has not been shown to stabilize the 
amorphous form against crystallization.  The rapid crystallization of the one sample that 
was completely amorphized indicates that there is no reaction occurring between the drug 
and the excipient which would interfere with the crystallization process.    The lack of 
stability of the amorphous form of astemizole when co-ground with Neusilin and the lack 
of complete amorphous conversion of pyrimethamine when co-ground with Neusilin 
indicates that the development of the amorphous form of a basic drug compound for 
commercial use would not be successful. 
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Chapter 6.  Sulindac 
 
Introduction 
Use of the amorphous phase to improve the oral bioavailability of poorly soluble 
drugs is well known.  From the standpoint of maximizing exposure the amorphous phase 
is of great interest for pharmaceutical scientists.  It is at a higher energy and offers the 
promise of higher solubility and faster dissolution rate and which delivers the potential to 
increase bioavailability.
1,2
  During development of a drug product these improvements 
are highly sought after for development as increased bioavailability can be used to 
enhance the performance of the final drug product.     
While the advantages of increased solubility and dissolution make the conversion 
from the crystalline form to amorphous appear favorable, chemical and physical stability 
issues as well as processing difficulties do exist..
3
  The amorphous form tends to be more 
chemically unstable than it’s crystalline counterparts.4  However from a development 
standpoint the physical instability is the most problematic.  The challenges to the stability 
of the amorphous form often result in a form change or reversion to the crystalline state. 
A typical approach to improve the physical stability of amorphous pharmaceuticals is to 
combine them with inactive ingredients such as polymers to form amorphous solid 
dispersions.  The challenges to stability are the main limiting factor in the use of 
amorphous material for drug development.  In fact amorphous materials are only rarely 
used when developing a drug product due to the processing and storage challenges 
caused by the decrease in chemical and physical stability.   
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The areas that require the most attention in developing amorphous drug material 
for product development is the stabilization of the amorphous form during all processing 
steps, long term stability and shelf life of the final product.  Although stabilization poses 
a challenging problem the promise of improvements in oral bioavailability make 
amorphization of a poorly soluble crystalline drug an attractive area for development.   
 Studies utilizing an acidic drug combined with an inorganic excipient 
demonstrated the most success at stabilization of an amorphous drug.  The stabilization 
mechanism has been attributed to interactions between the carboxyl group of the drug 
and reactive sites on the excipient brought about by co-grinding.  It has been suggested 
that the presence of an acidic group in the drug molecule may be required for a stable 
drug/excipient complex to form.  A mechanism for stabilization still needs to be 
established.     
In this study we report the production of the amorphous complex of an acidic 
drug, Sulindac with Neusilin US2 by cryo-milling, ball milling and hot melt extrusion.  
The physical/chemical stability and dissolution behavior of these amorphous complexes 
have been investigated.  As a method of scaling up production hot melt extrusion was 
identified as a method capable of continuous production of the amorphous drug/excipient 
complexes.   The nature of the mechanochemical reaction induced between Sulindac and 
Neusilin has been investigated using 
13
C SSNMR spectroscopy and the possible 
mechanism of amorphous stabilization is speculated. 
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Cryo-milling 
Cryo-milling was the initial milling technique used to initiate the conversion of  
Sulindac from the crystalline to the amorphous form.  Crystalline Sulindac was cryo-
milled as received with no excipients in 10 minute intervals for a total milling time of 60 
minutes.  Samples were removed at 40, 50 and 60 minutes for XRPD analysis.  The 
sample appears to be almost completely amorphous by 40 minutes with only the hint of 
crystalline peaks at 19.0, 21.8 and 24.6
o
 2 Theta.  These peaks have completely 
disappeared into the amorphous halo by 60 minutes as shown in figure 1.   
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Figure 1.  XRPD data of  unmilled and cryo-milled Sulindac with no excipients for 40, 50 
and 60 minutes.  Complete amorphization appears after 60 minutes of milling. 
 
 
The samples were placed in stability chambers in closed containers at 25
o
C/60% Relative 
Humidity and 40
o
C/75% Relative Humidity (RH).  After 24 hours the samples were 
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removed and analyzed using XRPD to determine if the sample had remained in the 
amorphous form or crystallized.  It was found that both samples had begun 
crystallization, although to different degrees.  Peaks can be seen growing in the 
amorphous halo on the samples from both stability conditions as shown in figure 2. 
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Figure 2.  XRPD data of 24 hour stability samples of cyro-milled Sulindac with no 
excipients stored at 25
o
C/60% RH and 40
o
C/75% RH.  Crystallization can be seen 
beginning in both samples. 
 
 
 Sulindac was then cryo-milled with Neusilin in a 1 to 1 ratio by weight.  Samples 
were milled in 10 minute intervals for a total time of 35 minutes with a sample removed 
for XRPD analysis after 20 minutes.  At 20 minutes small peaks indicating the presence 
of crystalline material were still present at 18.6, 21.5 and 24.3
o
 2 Theta.  By 35 minutes 
of milling time the peaks had become unresolved as shown in figure 3. 
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Figure 3.  XRPD data of Sulindac cryo-milled with Neusilin in a 1 to 1 ratio by weight 
for 20 and 35 minutes.  Amorphization is complete at 35 minutes. 
 
 
The milled samples were put on stability at 25
o
C/60% RH and 40
o
C/75% RH.  After 24 
hours the first sample was analyzed using XRPD.  The sample stored at 40
o
C/75% RH 
showed that crystallization had occurred but the sample at 25
o
C/60% RH showed no 
signs of crystallization.  The sample on stability at 25
o
C/60% RH was found to maintain 
stability in the amorphous form ultimately for 4 months as shown in figure 4.  Although 
stability for 4 months looked promising it was not long enough to justify further 
investigation of cryo-milled material for development as a drug product.   
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Figure 4.  XRPD data of stability samples of Sulindac cryo-milled with Neusilin in a 1 to 
1 weight ratio.  Storage conditions at 25
o
C/60% RH and 40
o
C/75% RH for 24 hours and 
at 25
o
C/60% RH for 4 months.  Stability in the amorphous phase is seen for 4 months at 
25
o
C/60% RH. 
 
 
 
Ball milling  
Crystalline Sulindac was ball milled as received with no excipients investigate the 
effect of mechanical grinding on the crystalline phase.  After 60 minutes of ball milling, 
no phase change was observed in the ground material.  The XRPD pattern of the ground 
material conforms to the as-received form II material as shown in figure 5.  A closer 
inspection of the XRPD pattern of the ground material shows that the diffraction peaks 
are broader than the as-received material indicating that crystallite size reduction and/or 
lattice distortions are introduced into the ground material.  Descamps et. al have shown 
that the position of the temperature of milling with respect to the glass transition 
temperature will determine the outcome of the milling product.
18,19
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Figure 5.  XRPD patterns of Sulindac (a) as-received and (b) ball milled for 60 minutes 
and (c) ball milled with Neusilin for 60 minutes.  
 
 
 
For example when -Indomethcin (Tg~42 °C) is ground at room temperature in a 
ball mill the final product is a mixture of 50% -indomethacin and 50% amorphous 
phase.  However when -indomethacin is ground at cryogenic temperatures complete 
amorphization is achieved.
20,21
  These results show that when temperature of milling is 
close to the glass transition temperature either transition between polymorphic varieties 
or no change in the original form can be expected.  However when the temperature of 
milling is far below the glass transition temperature complete amorphization can be 
expected as seen in the cryo milling data, figure 1.  Our results with the ball milling of 
Sulindac can be explained on the basis of this scheme.  Since ball milling at room 
temperature is close to the glass transition of Sulindac (~69 °C) no form conversion is 
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observed.  It was also observed that cryogenic milling of Sulindac for 60 minutes 
converts the material into an amorphous phase.  See figure 1.  However this amorphous 
phase rapidly recrystallizes when stored at ambient conditions as shown in figure 2.    
Sulindac was ball milled with Neusilin US2 in a 1 to 1 weight ratio for 60 
minutes.  The resulting mixture was confirmed to be amorphous by XRPD and the data 
are shown in Figure 5.   This indicates that the addition of Neusilin to the mixture 
facilitates amorphous formation during ball milling while ball milling of the as-received 
crystalline material did not result in amorphous formation.  Our results are consistent 
with that reported by Bogner et. al. for Indomethacin-Neusilin system.
12
  They observed 
that Neusilin promotes amorphous formation of Indomethacin during ball milling.  
Bogner et. al reported that it took nearly 10 days of co-grinding with Neusilin to achieve 
complete amorphization of Indomethacin.  In our study complete amorphization of 
Sulindac (as determined by XRPD) was achieved in 60 minutes.  This difference is most 
likely due to the different type of mill used in the two studies.  For their study Bogner et. 
al. used a low energy jar milling while high energy ball milling was used in this study.  
The ball milled amorphous complex was analyzed by modulated DSC and TGA.  A glass 
transition temperature for the amorphous complex could not be detected in MDSC 
measurement.  A clear glass transition was observed in DSC for amorphous Sulindac 
produced by melt quenching.  Although XRPD indicates that both materials are 
amorphous the DSC traces are significantly different indicating substantial difference 
between the two amorphous phases.  TGA analysis of the amorphous complex revealed a 
continuous weight loss of 4.1% from room temperature to 180
o
C associated with the 
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moisture loss from the sample.  The ball-milled sample was analyzed by HPLC and was 
found to be free of chemical degradation. 
In order to understand the nature of the amorphous complex formed by ball 
milling Sulindac with Neusilin, time course studies were initiated.  Sulindac was ball 
milled with Neusilin in a 1 to 1 weight ratio for 5, 20, 40, and 60 minutes.  The sample 
from each time point was analyzed by 
13
C SSNMR spectroscopy.  Figure 6 shows the 
13
C 
CP/MAS/TOSS spectra of Crystalline and melt-quenched amorphous Sulindac.  Some of 
the peaks in the spectra have been assigned based on comparison with solution NMR 
data.  The spectrum of the amorphous sample shows broader peaks when compared to the 
peaks in the crystalline sample reflecting the broader distribution of molecular 
orientations in the amorphous phase.  The peak labeled ‘4’ at 174.6ppm corresponding to 
the carboxyl group in the crystalline sample shows about a 3.2ppm upfield shift in the 
amorphous melt quenched sample.  The carboxyl peak at 171.4ppm in the amorphous 
material compares well with a 
13
C shift of 171.5ppm measured in solution.
22
  As the 
carboxyl region of the spectra provides a clear distinction between the amorphous and the 
crystalline sample, it was selected to monitor the mechanochemical changes occurring 
during ball milling.  The carboxyl region of 
13
C spectrum of Sulindac ball milled with 
Neusilin for different lengths of time is shown in Figure 7. 
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Figure 6.  
13
C CP/MAS/TOSS spectra of the crystalline and melt-quenched amorphous 
samples of Sulindac.  The dotted line shows the change in chemical shift of the carboxyl 
group in going from the crystalline to amorphous sample. 
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Figure 7.  Carboxyl region of the 
13
C CP/MAS spectra of crystalline Sulindac, melt-
quenched Sulindac and Sulindac ball milled with Neusilin at a 1:1 weight ratio for times 
indicated in the figure.  Ball milling progressively converts crystalline Sulindac ‘a’ into a 
mixture of amorphous Sulindac ‘b’ and amorphous Sulindac-Neusilin complex ‘c’.  The 
dotted lines are provided to aid visualization of data. 
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Ball milling progressively converts crystalline Sulindac (peak labeled ‘a’) into 
amorphous material.  Two types of amorphous phases are generated upon ball milling 
(peaks labeled ‘b’ and ‘c’).  The peak labeled ‘c’ corresponds to the amorphous melt 
quenched material.  However, the peak labeled ‘b’ corresponds to a distinct second 
amorphous phase.  This peak is associated with a complex formation between Neusilin 
and Sulindac.  A number of mechanisms have been proposed in literature for this 
complex formation during co-grinding of Indomethacin with Neusilin.  Watanabe et al. 
have proposed a hetero bridging bond formation between the carboxyl group of 
Indomethacin and surface silanol groups of Neusilin based on a number of experimental 
techniques.
23
  Bogner et al. have suggested that in addition to salt formation, ion-dipole 
interactions and/or hydrogen bonding between the carboxyl groups of Indomethacin and 
Silanol groups of Neusilin may also account for the changes observed in ATR-FTIR.  
Although the mechanism at this point is unclear, it is evident from the data presented 
some form of interaction between Sulindac and Neusilin occurs to provide a downfield 
chemical shift of the carboxyl group in the 
13
C SSNMR spectrum.  This can be explained 
through salt formation and/or hydrogen bonding.  However, bridging bond formation 
appears unlikely based on HPLC retention times being identical for the as-received 
crystalline material and the ball milled amorphous complex.  
In order to understand the kinetics of amorphous complex formation as a function 
of ball milling time the 
13
C SSNMR data in the carboxyl region was deconvoluted to 
provide relative amounts of the amorphous Sulindac and amorphous Sulindac-Neusilin.  
This analysis assumes equal cross polarization efficiency for the carboxyl peak of 
crystalline and amorphous phases.   The data are shown in Figure 8.   
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Figure 8.  Percentage of amorphous phase produced as a function of ball milling time: 
(●) Overall amount of amorphous material, (△) amount of amorphous Sulindac, and 
(□) amount of amorphous Sulindac-Neusilin complex. 
 
The overall kinetics of amorphous formation appears to be biphasic with the 
amount of amorphous formation increasing rapidly from 0 to 90% in the first 40 minutes 
then going to 100% from 40 to 60 minutes.  Bogner et al. have observed similar biphasic 
kinetics for amorphous formation in their study of Indomethacin with Neusilin.
12
  The 
kinetics of amorphous Sulindac formation parallels that of the overall kinetics of 
amorphous formation between 0 and 40 minutes, however the amount of amorphous 
Sulindac decreases between 40 and 60 minutes.  In contrast, the kinetics of amorphous 
complex formation increases linearly throughout the entire course of ball milling.  The 
slowdown in kinetics of the overall amorphous formation in last 20 minutes of milling is 
attributed to the progressive conversion of the amorphous Sulindac into the amorphous 
Sulindac-Neusilin complex. 
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Hot melt extrusion (HME) of Sulindac-Neusilin mixtures 
While ball milling provides a convenient route to generate small quantities of 
Sulindac-Neusilin amorphous complexes in the lab it is not a scalable process.  HME was 
explored as a means of scaling up the production of these complexes.  HME can be used 
as a mechano-chemical process because it allows close material packing with efficient 
mixing, milling, and temperature control.  The advantage over more traditional 
technologies (e.g. ball milling) is that HME is a continuous process that is more easily 
scaled to pharmaceutically relevant batch sizes.  Additionally HME has the advantage of 
being a ‘green chemistry’ technology that needs little or no solvents.  The process can be 
readily monitored and controlled i.e. screw speed, feed rate, throughput, temperature, 
mixing, shear, and conveying ability.  The HME screw design used for generating the 
amorphous complexes is shown in Figure 7(a).  The screw design is customized to 
include several mixing and conveying elements. 
13
C SSNMR data in the carboxyl region for samples made by HME are shown in 
Figure 7(b).   HME was initially attempted at 150
o
C at two screw speeds 50 and 200 rpm 
to investigate whether the complex formation occurs below the melting point of Sulindac 
(184 .6
o
C).  Different screw speeds were used to change the residence time of the 
material in the extruder barrel.  It is clear from the SSNMR data presented that no 
conversion was observed at this temperature irrespective of the screw speed used.  
However conversion of the crystalline material to the amorphous complex was observed 
when HME was conducted at a temperature of 200
o
C which was above the melting point 
of Sulindac.  Thus, temperatures above the melting point of Sulindac are required to 
effect the conversion to the amorphous complex.  Consistent with ball milling, HME 
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produced samples containing a mixture of the amorphous Sulindac (peak ‘b’) and 
amorphous Sulindac-Neusilin complex (peak ‘c’).  Notably the amount of the complex 
formed was found to be greater than that achieved from ball milling for 60 minutes.  The 
amount of complex formed remained about the same irrespective of the starting 
composition of Sulindac to Neusilin.  This shows that Neusilin amounts greater than 1:1 
do not serve to increase the amount of complex formed under these experimental 
conditions.  About 100 grams of 1:1 and 1:2 complexes were produced using HME at 200 
o
C with a screw speed at 50 rpm.  The sample was recovered as a powder from the HME 
apparatus.  The HME samples were analyzed by HPLC and were found to be free of 
chemical degradation.  HME thus provides an efficient and a convenient route to the 
continuous production of Sulindac-Neusilin amorphous complexes. 
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(a) 
 
 
(b) 
 
Figure 9.  (a) HME screw design used to generate amorphous complexes.  (b) 
Carboxyl region of the 
13C CP/MAS spectra of HME samples.  Peak labels: ‘a’ 
crystalline Sulindac, ‘b’ amorphous Sulindac, and ‘c’ amorphous Sulindac-Neusilin 
complex.   
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The surface area of crystalline Sulindac and Sulindac-Neusilin amorphous 
complexes as measured by Kr BET are shown in Table 1.  The surface area of Neusilin 
US2 is consistent with that reported in product literature.  The measured surface area of 
as-received crystalline Sulindac was 1 m
2
/g which is consistent with what can be 
expected for an un-milled pharmaceutical compound. The 1:1 Sulindac-Neusilin 
amorphous complexes produced by either ball milling or by HME have a much lower 
surface area than expected average value of about 156m
2
/g.  This data indicates that 
complexation between Neusilin and Sulindac occurs at the surface of Neusilin.  As an 
outcome of this solid state reaction the pores in Neusilin are no longer available for the 
Krypton gas to probe leading to a reduced surface area.  The surface area for the HME 
sample is lower than that of the ball-milled sample showing higher extent of reaction for 
the HME sample.  The surface area of 1:2 Sulindac-Neusilin amorphous complex 
produced by HME has a much higher surface area than the 1:1 complex.  This surface 
area of 91m
2
/g is closer to the expected average value of about 102m
2
/g.  This shows the 
addition of more Neusilin beyond the 1:1 ratio does not impact the extent of surface solid 
state reaction.  The extent of reaction predicted by surface area results are in good 
agreement with those obtained by 
13
C SSNMR.  Moreover this data also shows that 
Sulindac does not penetrate the pores of Neusilin and thereby does not get confined in the 
mesopores of Neusilin.  This result is not surprising given the short residence time in the 
extruder.  Thus, production of Sulindac-Neusilin using HME saturates complex formation 
at a 1:1 weight ratio and does not confine Sulindac to the pores of Neusilin.    
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Sample Surface Area (m
2
/g) 
Neusilin 304.0 
Crystalline Sulindac 1.0 
Sul-Neu  Ball milled  
60 minutes 
4.8 
Sul-Neu 1:1 HME 2.2 
Sul-Neu 1:2 HME 91.2 
Sul-Neu 1:1 PhysMix 115.0 
Table 1.  Surface area of Sulindac/Neusilin samples measured using Kr-BET analysis. 
 
 
 
Physical stability of ball milled and HME samples 
Figure 10 shows the XRPD patterns of 1:1 ball-milled (BM) and 1:1/1:2 HME 
samples as a function of time at 40
o
C/75% RH.  The XRPD pattern for the time zero 
samples showed a broad halo without any characteristic reflections typical of the 
amorphous phase.  The BM and HME samples remained amorphous after 3 and 4 months 
storage at 40
o
C/75% RH respectively.  Moreover all samples were found to remain 
amorphous for more than a year at ambient conditions (data not shown).  At the time 
points shown in Figure 10, the samples were analyzed by HPLC and were found to be 
free of chemical degradation.  This demonstrates that either ball milling or hot melt 
extruding of Sulindac with Neusilin provides both physically and chemically stable 
amorphous phase.   
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Figure 10.  XRPD samples of Ball milled (BM) and hot-melt extruded (HME) samples as 
a function of time at 40
o
C/75% RH.  All samples remained amorphous for 3 to 4 months 
at accelerated stress conditions. 
 
 
Our results are consistent with other observations in literature where acidic 
compounds such as Indomethacin and Aceclofenac showed good physical stability for 
periods of one to three months at 40
o
C/75% RH when co-ground with Neusilin.
11,24
  
Moreover it has been shown that there is a reduction in the crystallinity of partially 
crystalline drug-Neusilin complexes upon storage at accelerated conditions.  As it is 
thermodynamically impossible to convert a crystalline material to its amorphous 
counterpart spontaneously (without input of energy), such a conversion as described in 
literature must be mediated by a phase change involving Neusilin.  This complex 
formation of acidic drugs with Neusilin helps the stabilization of amorphous phase.  Thus 
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Neusilin provides additional avenue of stabilization when compared to organic polymer 
excipients.   
 
Dissolution of Ball milled and HME samples in 0.1N HCl 
Dissolution profiles of crystalline Sulindac and Sulindac-Neusilin amorphous 
complexes in 0.1N HCl are shown in Figure 11.  Crystalline Sulindac is poorly soluble in 
the medium and reaches a solubility of 3g/mL in about 60 minutes.  In contrast the 
Sulindac-Neusilin amorphous complexes showed faster dissolution rate and higher 
solubility.  The HME samples show a peak concentration and a plateau concentration.  
For 1:1 HME sample the peak concentration was 19.4g/mL while the peak 
concentration for the 1:2 HME sample was 32.1g/mL.  The plateau concentration for 
both samples was around 13.2 to 13.4g/mL.  In contrast the ball milled 1:1 sample 
showed a peak concentration of 15.1g/mL and a plateau concentration of 14.4g/mL.  
The peak to plateau ratio follows the order 1:2 HME> 1:1 HME>1:1 ball milled.  The 
peak concentration for all samples was attained within 10-17 minutes.  Similar 
dissolution behavior has also been observed for Indomethacin-Neusilin amorphous 
complexes.
25
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Figure 11. Dissolution profiles in 0.1N HCl: () Crystalline Sulindac, () 
Sulindac:Neusilin 1:1 ball milled, (Δ) Sulindac:Neusilin 1:1 HME, and () 
Sulindac:Neusilin 1:2 HME. 
 
 
 
Crystalline Sulindac did not show any appreciable improvement in dissolution or 
solubility when Neusilin was added to the dissolution media.  The presence of Neusilin 
cannot explain the increased plateau concentration observed for the amorphous 
complexes.  In order to understand the dissolution behavior the amorphous complexes 
were slurried in 0.1N HCl in a separate experiment.  Solids recovered from the slurry 
after about 20 minutes showed conversion to the crystalline material by XRPD.  
Interestingly all samples had converted to the metastable anhydrous Form I (data not 
shown).  It has been reported that Form I has a solubility five to seven fold higher than 
the more stable Form II at room temperature.
26
  During dissolution the conversion to the 
metastable polymorph occurs leading to a drop from the peak concentration towards the 
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plateau concentration which is about 5 fold higher than the plateau concentration 
observed for the more stable form II.  The increase in the peak to plateau ratio for the 1:2 
HME sample can be attributed to the microenvironmental pH increase provided by the 
excess Neusilin.  In summary, the amorphous Sulindac-Neusilin complexes are able to 
provide enhanced dissolution rate and solubility when compared to the as-received 
crystalline material. 
 
Dissolution of drug product of Sulindac-Neusilin complexes 
For the solubility/dissolution advantage of the Sulindac-Neusilin complexes to be 
translatable to the clinic a viable drug product has to be demonstrated.  To this end tablets 
were made from the 1:1 HME amorphous complex and these were compared with the 
commercial Sulindac tablets.  The composition of the tablets is shown in Table 2.   
 
Component Commercial tablet 1:1 HME tablet 
Weight (mgs) Weight % Weight (mgs) Weight % 
Sulindac 200 60.6 200 40 
Neusilin - - 200 40 
Starch 1500 * * 47.5 9.5 
Avicel PH 102 * * 47.5 9.5 
Magnesium Stearate * * 5.0 1 
Total tablet weight 330 100 500 100 
Table 2.  Compositions of commercial crystalline Sulindac and 1:1 Sulindac/Neusilin 
HME amorphous tablets.  The exact weights of Starch, Avicel, and Magnesium Stearate 
used in the commercial tablet is not known.  Neusilin was not used in the commercial 
tablet. 
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Although the total weight of the two tablets was different the amount of active 
drug in both tablets was kept the same.  The dissolution comparison of the 1:1 HME and 
commercial tablets in 0.1N HCl is shown in Figure 12(a).  Surprisingly, the tablets made 
from the 1:1 amorphous complex did not provide any dissolution advantage when 
compared to the commercial tablets made from crystalline material.  The tablets made 
from amorphous complex were then analyzed by XRPD and were found to have 
crystallized into Form II  thereby negating the solubility/dissolution advantage as shown 
in figure 12(b).    
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 Figure 12. (a) Tablet dissolution in 0.1 N HCl: () Commercial tablet containing Form II 
Sulindac and () Tablet containing 1:1 HME Sulindac-Neusilin complex.  (b) XRPD of 
tablet containing 1:1 HME Sulindac-Neusilin complex.  
 
 
The 1:1 HME drug product was analyzed nine months after manufacture.  The 
data shows that while the amorphous drug substance is stable at ambient conditions the 
drug product becomes physically unstable.  The crystallization in the drug product could 
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be due to (a) interaction with excipients, (b) compressive forces used in tabletting, or (c) 
a combination of excipient interaction and compression.   A preliminary blending study 
of 1:1 HME powder with excipients and compression of either amorphous powder by 
itself or in combination with excipients did not produce the phase change to the 
crystalline substance although Magnesium Stearate containing blends showed trace 
amount of crystallinity. This data could not be unambiguously confirmed.  Thus the 
change in crystallinity was attributed the propensity of the 1:1 HME sample to slowly 
crystallize over a period of time.  In fact, after 15 months of storage at ambient conditions 
the 1:1 HME sample was found to have crystallized.  However in the drug product 
crystallization occurs after nine months of storage at ambient conditions.  Thus the 
crystallization is accelerated in the drug product.  With crystallization occurring over 
such long periods it is difficult to identify the excipient responsible for promoting 
crystallization in the drug product.   
It was observed that even after 17 months of storage at ambient conditions the 1:2 
HME sample was still amorphous.  Tablets were made with the 1:2 HME sample and 
were analyzed by dissolution.  For exact comparison tablets were also made using the 
same1:2 compositions with crystalline Sulindac and Neusilin.  The composition of the 
tablets is shown in Table 3.  The composition was changed to include stearic acid and 
HPMC.  Stearic acid was chosen to replace Magnesium Stearate as the lubricant as it was 
suspected to promote crystallization of the amorphous complex.  HPMC E4 was added as 
an agent to sustain super saturation.  The ability of HPMC in maintaining super saturation 
is well documented.
27-30
  The tablets were confirmed to be amorphous and crystalline by 
XRPD.  The data for the physical form in the tablets in presented in Figure 13(a). 
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Component 1:2 crystalline tablet 1:2 HME tablet 
Weight (mgs) Weight % Weight (mgs) Weight % 
Sulindac 50 25 50 25 
Neusilin 100 50 100 50 
Starch 1500 20 10 20 10 
Avicel PH 102 20 10 20 10 
Stearic acid 2 1 2 1 
HPMC E4 8 4 8 4 
Total tablet weight 200 100 200 100 
Table 3.  Compositions of crystalline and HME amorphous 1:2 Sulindac/Neusilin tablets. 
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 Figure 13. (a) XRPD of crystalline Sulindac, 1:2 Crystalline Sulindac/Neusilin tablet, 
and 1:2 HME amorphous Sulindac/Neusilin tablet.  (b) Dissolution in 0.1 N HCl: ()1:2 
Crystalline Sulindac/Neusilin tablet and ()1:2 HME amorphous sulindac/Neusilin 
tablet. 
The dissolution comparison between the 1:2 tablets made from crystalline and 
amorphous HME Sulindac-Neusilin complex are shown in Figure 13(b).  The crystalline 
Sulindac tablet reached a final concentration of 5.7g/mL with 9% release in 90 minutes 
which compares well with powder dissolution data of crystalline Sulindac.  In contrast to 
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the 1:2 crystalline tablets, the 1:2 HME tablet reaches a concentration of 56g/mL with 
100% release in 90 minutes.  It may be recalled from the powder dissolution data 
presented in Figure 11, 1:2 HME amorphous powder showed a peak concentration of 
32.1g/mL and a plateau concentration of 13.4g/mL.   The drop from the peak to the 
plateau was attributed to crystallization in the powder sample. Clearly the tablet made 
from 1:2 HME amorphous powder sample outperforms the commercial tablet while also 
overcoming the problem of crystallization seen in the 1:2 HME powder sample during 
dissolution.  Excipients such as HPMC added to the tablet may have helped in 
maintaining the super saturation, thereby preventing crystallization of Sulindac in the 
dissolution medium.  Judicious choice of excipients during tablet formulation can help in 
the realizing the full potential (in terms of solubility and dissolution) of amorphous acidic 
drug-Neusilin complexes. 
 
Choice of polymers to stabilize the amorphous phase  
Traditionally amorphous pharmaceutical solids have been stabilized using organic 
polymers.  A number of mechanisms have been proposed by which organic polymers 
stabilize the amorphous pharmaceutical.  However, all these mechanisms involve some 
form of physical interaction such as hydrogen bonding or Van-Der Waals forces.  
Moreover the polymer which typically has higher glass transition than the amorphous 
pharmaceutical, can serve as a diffusional barrier to recrystallization.  The extent of phase 
mixing and the degree of physical interaction between the organic polymer and the 
amorphous pharmaceutical will determine the physical stability of the amorphous 
pharmaceutical.   
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Inorganic polymers such as silicates have also been reported to stabilize 
amorphous pharmaceuticals.  In contrast to their organic counterparts, some inorganic 
polymers such as Neusilin US2 have the potential to form salts with acidic compounds in 
addition to other physical interactions such as hydrogen bonding and dipole-dipole 
interactions.  As discussed in this paper this additional stabilization mechanism can 
impart greater solid state stability.   For example amorphous Sulindac crystallizes within 
24 hours at ambient conditions.  Sulindac/Polyvinylpyrrolidone (1:1) amorphous 
dispersions crystallize within 2 weeks at 40
o
C/75% RH.  However Sulindac-Neusilin 
amorphous mixtures at both 1:1 and 1:2 weight ratios are stable for up to 3 months at 
40
o
C/75% RH.  This additional stability imparted by Neusilin correlates with its potential 
to form amorphous salt complexes with acidic drugs.  In addition Neusilin US2 is also an 
adsorbent for moisture because of its high surface area.  As it is able to absorb a high 
levels of moisture it acts as moisture sink thereby protecting the amorphous API from the 
effects of moisture.  These properties of Neusilin US2 make it an ideal choice for 
stabilizing amorphous acidic drugs.  This fact has been demonstrated for many acidic 
API’s such as Indomethacin, Ketoprofen, Naproxen11, Ibuprofen16 and Aceclofenac24 
when they are co-ground with inorganic silicates.   
However with neutral and basic drugs the situation with respect to Neusilin 
stabilization is less clear.  Silicates have been reported to stabilize non-acidic drugs such 
as progesterone and TAS-301.   The advantage of using silicates over organic polymers 
for non-acidic drugs is not obvious since stabilization with silicates will occur along the 
same lines as discussed for organic polymers.  Again, for silicates containing other metal 
ions such as magnesium and aluminum like Neusilin, ion-dipole interactions may also 
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provide another mechanism for stabilization.  In the case of non-acidic drugs the stability 
enhancement provided by Neusilin will have to be investigated on a case by case basis.  
However for the broad class of acidic drugs containing the carboxyl moiety, Neusilin or 
other similar silicates would be better choices to stabilize amorphous phase than organic 
polymers.   
While advantages of using Neusilin-type silicates are apparent a mention must be 
made about the methods that are used to make these amorphous complexes at scale.  
Typically amorphous solid dispersions made using organic polymers can be scaled using 
processes that involve solvent such as spray drying, lyophilization, and solvent 
precipitation, or by dry process such as HME.
31
  However production of amorphous 
complexes with inorganic excipients can only be accomplished by a process such as 
HME.  As mentioned in the preceding sections the stabilizing power of the complex is 
due to the ability of the silicate to form a salt with the API.  This reaction is driven by 
employing temperatures close to the melting point of the API.  As such only a method 
like HME can be used to produce large quantities of these complexes.  While processes 
involving solvent like spray drying may be used to generate amorphous API/Neusilin 
mixtures they will not be able to generate the desired complex and thereby the physical 
stability of the amorphous material may be compromised. 
 
 
Conclusions 
The use of an inorganic magnesium aluminum metasilicate to stabilize the 
amorphous form of Sulindac was explored in this paper.  Ball milling of crystalline 
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Sulindac with Neusilin in a weight ratio of 1:1 was able to produce an amorphous 
complex that was found to be physically and chemically stable at 40
o
C/75% RH for a 
period of 4 months.  
13
C SSNMR measurements of ball milled samples indicated the 
presence of two types of amorphous materials namely: amorphous Sulindac and 
amorphous Sulindac-Neusilin complexes.  Moreover NMR measurements also indicate 
the formation of salt between Sulindac and Neusilin.  The excellent physical stability of 
these complexes was attributed to this unique phenomenon of salt formation.  HME was 
demonstrated as a method capable of producing these complexes at scale.  In addition to 
the production of the amorphous complex, a viable tablet formulation was demonstrated 
with these complexes.  The tablets made from the 1:2 Sulindac-Neusilin amorphous 
complex showed 100% release in 0.1N HCl medium while the corresponding tablet made 
from the crystalline material showed only a 9% release.  It was shown that care must be 
employed while selecting the components of the formulation to make the drug product 
not only to maintain the physical stability of the amorphous complex but also to enhance 
the dissolution properties.  While Neusilin clearly provides an advantage in stabilizing 
acidic drugs that contain the carboxyl moiety more work needs to be done to extend the 
utility of Neusilin to basic and neutral drugs.   
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Chapter 7.  Conclusions and Future Considerations 
 
The use of amorphous drugs for drug product development carries with it certain 
challenges namely, the chemical and physical instability that is the nature of amorphous 
material.  With the challenges come some rewards in the form of increased dissolution 
rate and bioavailability.  Manipulating these characteristics toward the improvement of 
drug performance during development are some of the primary goals of the 
pharmaceutical chemist.  The pursuit of these goals results in the development new 
methods and materials being constantly explored.    
Organic excipients mixed with the amorphous form of a drug have been shown to 
help stabilize against crystallization by various mechanisms.
1-6
   The main advantage to 
the use of organic polymers is that the amorphous solid dispersions are able to maintain 
the original dissolution and solubility advantages of the original amorphous drug 
material.  Several methods for the mechanism of stabilization of the amorphous drug 
material using organic polymers have been proposed.  These include hydrogen bonding 
between the excipient and drug, steric hindrance caused by the polymer to prevent 
crystallization of the amorphous material and an increased glass transition temperature as 
a result of the production of a single phase mixture between the polymer and amorphous 
drug.   
Recent work has been done utilizing inorganic silicates in the stabilization of 
amorphous drug material.  Inorganic silicates provide the possibility of stabilization of 
amorphous API through the unique mechanism of salt formation, a mechanism not 
available when using organic polymers.  An interesting inorganic silicate Neusilin, a 
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synthetic magnesium aluminometasilicate, has been demonstrated to aid in the 
amorphization process resulting in a higher percentage of amorphous material formed as 
opposed to processing without an excipient.  Hydrogen bonding or acid-base reactions 
between the drug and silanols and possible ion-dipole interactions between the drug and 
metal ions at the surface of Neusilin are the proposed mechanisms for stabilization.
.
   
Both cryo-milling and ball milling were found to produce the amorphous form of 
Sulindac when milled either with or without Neusilin however amorphous Sulindac 
milled without Neusilin crystallized within 24 hours.  Both griseofulvin and astemizole 
resisted amorphization when cryo-milled without the addition of Neusilin.  Griseofulvin 
was amorphized when ball milled with and without the addition of Neusilin yet all 
amorphous samples of griseofulvin crystallized within 24 hours.  The addition of 
Neusilin was found to be a requirement for the amorphization of both griseofulvin and 
astemizole although astemizole was only cryo-milled and not ball milled.  Due to the lack 
of availability of astemizole, pyrimethamine was chosen as a replacement as it is also a 
basic compound.  Pyrimethamine was not amorphized during ball milling even with the 
addition of Neusilin.  The amorphous Sulindac/Neusilin complex formed upon ball 
milling was found to have the longest term stability out of all samples generated. The 
amorphous griseofulvin/Neusilin samples and amorphous astemizole/Neusilin samples 
were found to crystallize within 24 hours of milling regardless of milling technique used.  
As a result, the amorphous Sulindac/Neusilin complex became the focus of the 
investigation.  
 The formation of a complex between the amorphous Sulindac and Neusilin upon 
milling was the cause for resulting stability of the amorphous form.  The most likely 
97 
 
mechanisms for stabilization of the Sulindac/Neusilin complex were determined upon 
13
CSSNMR analysis and showed the formation of a salt between the amorphous Sulindac 
and Neusilin.   
 Bench top mills were very effective in the amorphization and complex formation 
of the Sulindac/Neusilin samples but this bench top process cannot be scaled up.  Without 
the ability to scale up the batch size the process cannot be used for any commercial 
applications rendering it useless for development.  Because the amorphous 
Sulindac/Neusilin samples generated from ball milling were more stable than the ones 
generated from cryo-milling it was determined that temperature during milling has a 
significant effect on the outcome of stability.  Hot Melt Extrusion (HME) was identified 
as a possible means to scale up production of the amorphous drug/excipient complex.  
The HME extruded samples demonstrated not only a greater percentage of amorphization 
of the Sulindac but also greater long term stability of the Sulindac/Neusilin complex.  
Because the quality of the HME samples were superior to what the ball mill produced it 
was determined that HME was a viable method to scale up production enough to enable 
further development of the amorphous complex. 
 Because the formation of a useful drug product is the final goal for 
Pharmaceutical development a drug product was made using the HME complex.  Tablets 
containing the HME complex were manufactured using the same recipe as commercially 
available Sulindac tablets marketed under the name Clinoril and use crystalline Sulindac.  
It was expected that the tablets using amorphous drug would show improved dissolution 
over the tablets using crystalline material.  This did not turn out to be true.  The 
dissolution profile was the same for both the crystalline and amorphous tablets.  A study 
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was initiated to determine if the added excipients had contributed to the crystallization of 
the tablets containing the HME material.  It was found that Magnesium Stearate was 
causing the amorphous HME Sulindac/Neusilin complex to crystallize prior to 
compression into tablets.   
A new tablet blend was developed replacing the Magnesium Stearate with Stearic 
Acid and adding Hydroxypropylmethylcellulose as an additional excipient.  The 1:1 
HME Sulindac/Neusilin material was found to have crystallized during storage.  It was 
replaced with 1:2 HME Sulindac/Neusilin material which proved to have remained 
amorphous.  The experiment was run again and this time the tablets containing the HME 
amorphous Sulindac/Neusilin complex demonstrated a marked improvement in the 
dissolution rate over the tablets containing the crystalline material.  Stability analysis of 
the tablets stored at both 5
o
C and 40
o
C/75% RH using XRPD shows that the tablets 
remained amorphous after 4 weeks. 
  The goals set for determining the feasibility of the use of amorphous drug 
material in a drug product were successfully met.  Crystalline drug material was reliably 
amorphized using an optimized ball milling method and stabilized with the addition of 
the inorganic excipient, Neusilin.  The scale up of the stable amorphous drug-excipient 
complex was achieved using a solventless HME process and tablets were produced using 
the amorphous material from the scaled up process.  These tablets have demonstrated an 
improvement in the dissolution rate over the tablets made using crystalline drug material.  
The tablets made from the 1:2 Sulindac-Neusilin amorphous complex showed 100% 
release in 0.1N HCl medium while the corresponding tablet made from the crystalline 
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material showed only a 9% release and have remained stabilized against crystallization 
for one month at 5
o
C and 40
o
C/75%RH.   
These results indicate that the development of a drug product using the 
amorphous form of a crystalline drug can not only be done but also promises to provide 
improvements upon the original drug product.  It is known that an improvement in 
dissolution can relate to an improvement in bioavailability.  If the bioavailability were to 
show the expected improvement in the amorphous drug product, then drug load in the 
new product could be lower.  This has the added benefit of lowering the production costs 
of the drug by lowering the amount of drug produced while keeping the efficacy of the 
drug product the same.  While Neusilin clearly provides an advantage in stabilizing acidic 
drugs that contain the carboxyl required for salt formation further investigation is 
required to extend the utility of Neusilin to basic and neutral drugs.   
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